Abstract
Immunotherapy using immune-checkpoint modulators revolutionizes the oncology field far beyond their remarkable clinical efficacy in some patients. It creates radical changes in the evaluation of treatment efficacy and toxicity with a more holistic vision of the patient with cancer.
Keywords
ImmunotherapyMedicineImmune checkpointCancer immunotherapyCancerCancer therapyImmune systemOncologyCancer researchInternal medicineImmunology
MeSH Terms
AntibodiesMonoclonalAntibodiesMonoclonalHumanizedAntineoplastic AgentsImmunologicalB7-H1 AntigenCTLA-4 AntigenHumansImmunotherapyIpilimumabNeoplasmsNivolumabProgrammed Cell Death 1 Receptor
Affiliated Institutions
Related Publications
A review of cancer immunotherapy toxicity
Abstract Cancer immunotherapies, including checkpoint inhibitors and adoptive cell therapy, manipulate the immune system to recognize and attack cancer cells. These therapies ha...
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protei...
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Purpose Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and ...
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-...
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Melanoma, a skin cancer associated with high mortality rates, is highly radio- and chemotherapy resistant but can also be very immunogenic. These circumstances have led to a rec...
Publication Info
- Year
- 2020
- Type
- article
- Volume
- 11
- Issue
- 1
- Pages
- 3801-3801
- Citations
- 1463
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
1463
OpenAlex
38
Influential
Cite This
Caroline Robert
(2020).
A decade of immune-checkpoint inhibitors in cancer therapy.
Nature Communications
, 11
(1)
, 3801-3801.
https://doi.org/10.1038/s41467-020-17670-y
Identifiers
- DOI
- 10.1038/s41467-020-17670-y
- PMID
- 32732879
- PMCID
- PMC7393098